CI vs OMCL: fair value comparison
The Cigna Group and Omnicell, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, CI currently sits closer to the top of our discount ranking. OMCL carries the stronger quality grade.
| CI | OMCL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $280.76 | $34.51 |
| 12-month range | $244.41–$289.26 | $29.96–$48.70 |
| Sector rank | #39 of 113 Healthcare | #42 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: CI fair value analysis · OMCL fair value analysis